GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLAUKOS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$166.96+2.12 (+1.29%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- –
- Dividend yield
- –
GLAUKOS Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | $421.07M | $303.28M | $237.04M | $214.24M | $231.98M | $179.36M | $230.97M | $181.28M | $159.25M | – | 83.0% | +38.8% |
| Corneal Health | $86.37M | $80.21M | $77.67M | $68.62M | $62.03M | $45.60M | $6.02M | – | – | – | 17.0% | +7.7% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $375.04M | $270.09M | $219.40M | $203.24M | $223.79M | $173.09M | $192.46M | $151.68M | $140.90M | $105.00M | 73.9% | +38.9% |
| International | $132.40M | $113.39M | $95.32M | $79.62M | $70.22M | $51.87M | $44.53M | $29.60M | $18.35M | $9.40M | 26.1% | +16.8% |
From the segment and revenue-disaggregation notes of Glaukos's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.